Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Kooienga

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Seminars in Dialysis|July 20, 2007
Phosphorus balance with daily dialysisLaura Kooienga
Hemodialysis International. International Symposium on Home Hemodialysis|June 30, 2006
Phosphate binders: new products and challengesAntonio Bellasi, Laura Kooienga, Geoffrey A Block
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 3, 2009
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKDLaura Kooienga, Linda Fried, Robert Scragg, et al.
Journal of Nephrology|April 23, 2009
How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?Antonio Bellasi, Laura Kooienga, Geoffrey A Block, et al.
Journal of Clinical Medicine|November 14, 2023
A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the EvidenceMohit Mathur, Tak Mao Chan, Kook-Hwan Oh, et al.
Kidney International|June 7, 2025
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathyLaura Kooienga, Jeannette Lo, Eun Young Lee, et al.
The New England Journal of Medicine|November 2, 2023
A Phase 2 Trial of Sibeprenlimab in Patients with IgA NephropathyMohit Mathur, Jonathan Barratt, Bobby Chacko, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2012
Effects of phosphate binders in moderate CKDGeoffrey A Block, David C Wheeler, Martha S Persky, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Seminars in Dialysis|July 20, 2007
Phosphorus balance with daily dialysisLaura Kooienga
Hemodialysis International. International Symposium on Home Hemodialysis|June 30, 2006
Phosphate binders: new products and challengesAntonio Bellasi, Laura Kooienga, Geoffrey A Block
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 3, 2009
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKDLaura Kooienga, Linda Fried, Robert Scragg, et al.
Journal of Nephrology|April 23, 2009
How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?Antonio Bellasi, Laura Kooienga, Geoffrey A Block, et al.
Journal of Clinical Medicine|November 14, 2023
A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the EvidenceMohit Mathur, Tak Mao Chan, Kook-Hwan Oh, et al.
Kidney International|June 7, 2025
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathyLaura Kooienga, Jeannette Lo, Eun Young Lee, et al.
The New England Journal of Medicine|November 2, 2023
A Phase 2 Trial of Sibeprenlimab in Patients with IgA NephropathyMohit Mathur, Jonathan Barratt, Bobby Chacko, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2012
Effects of phosphate binders in moderate CKDGeoffrey A Block, David C Wheeler, Martha S Persky, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.
Pageof 1